Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on March 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update
On track to submit New Drug Application for brexanolone for postpartum depression in 1H 2018 following pre-NDA meeting; buildout of commercial infrastructure underway for potential 1H 2019 launch Breakthrough Therapy designation for SAGE-217 offers potential for expedited development of major
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, February 22, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on
View HTML
Toggle Summary Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at
View HTML
Toggle Summary Sage Therapeutics Prices Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,506,098
View HTML
Toggle Summary Sage Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $575.0
View HTML
Toggle Summary Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder
– Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from depression – – Sage has received two Breakthrough Therapy designations for separate psychiatric drug candidates, reinforcing the Company’s
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces Positive Results from Placebo-Controlled Trial in a Model of Insomnia Demonstrating Activity on Sleep Parameters and Supporting Development of SAGE-217 as Potential Treatment for Sleep Disorders
– SAGE-217 met primary endpoint of improved sleep efficiency and demonstrated improvements in maintaining sleep compared to placebo – – Secondary endpoint measures demonstrated clear dose response with statistical significance in total sleep time and time spent awake after sleep onset – – Data
View HTML
Toggle Summary Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company
– Company evolving, as planned, to be a leading, innovative CNS company – – 2018 strategy focuses on continued R&D innovation, pipeline expansion and commercialization plans for new classes of CNS therapeutics – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan.
View HTML